Diadema Partners’s Sagimet Biosciences SGMT Stock Holding History

Diadema Partners’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-46,019	Closed	-$150K	–	129
2025 Q1	$150K	Buy	+46,019	New	+$193K	0.04%	96

Other funds holding SGMT

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

BOCH

Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

RAM

Readystate Asset Management Chicago, Illinois $2.93B AUM 18.57% 1-Year Est. Return

Diadema Partners's SGMT Position: Q2 2025 in Review

Diadema Partners sold out of Sagimet Biosciences (SGMT) in Q2 2025, closing a stake of 46,019 shares — an estimated $150K sold.

Diadema Partners first reported a position in SGMT in Q1 2025 and held it in 1 quarter. The position peaked at $150K in Q1 2025. 67 funds tracked by Wall St. Rank hold SGMT as of Q2 2025.

Diadema Partners reported no remaining Sagimet Biosciences position as of Q2 2025 after selling out during the quarter.
Diadema Partners sold 46,019 Sagimet Biosciences shares in Q2 2025, an estimated $150K.
Diadema Partners first reported a position in Sagimet Biosciences in Q1 2025 and held it in 1 quarter.
Diadema Partners's Sagimet Biosciences position peaked at $150K in Q1 2025.
67 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2025.

Based on Diadema Partners's 13F filing for Q2 2025, filed 14 Aug 2025.